Citi analyst Geoff Meacham initiated coverage of 89bio (ETNB) with a Buy rating and $25 price target Healthcare policy remains a key biopharma sector uncertainty but major economic worries have underscored the defensive attributes of biotech, the analyst tells investors in a research note. The firm says that despite near-term “choppiness,” a “barbell approach” to the sector still makes sense with higher-growth large caps likely able to absorb potential policy headwinds and catalyst-driven small-cap biotechs being insulated from macro uncertainties. Citi’s preferred smaller caps are focused on unmet medical needs, have differentiated research and development platforms or are “clean growth stories.” The firm highlights Apogee, Avidity, and Kymera as favorites.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ETNB:
- 89Bio Inc. Faces Financial Risks Amid Market Challenges for Approved Products
- 89bio Inc. Advances Clinical Trials Amid Financial Losses
- 89bio price target lowered to $21 from $29 at H.C. Wainwright
- 89bio reports Q4 EPS ($1.02), consensus (76c)
- ETNB Insider Trade Alert! Majority Shareholder Buys $50M Worth of 89bio Stock